News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genmab A/S (GEN.CO) Reaches Third Milestone in H. Lundbeck A/S (LUN.CO) Collaboration


12/13/2012 9:51:41 AM

Copenhagen, Denmark; December 13, 2012 – Genmab A/S (OMX: GEN) announced today it had reached the third pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment (approximately DKK 7.5 million). Under the collaboration with Lundbeck, Genmab creates novel human antibodies to three central nervous system (CNS) targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES